
Tucatinib is approved by NICE for HER2+ metastatic breast cancer
METUPUK welcome the National Institute of Clinical Excellence (NICE) decision to accept Tucatinib with trastuzumab and capecitabine for treating HER2-positive unresectable locally advanced or…
Read more








